Pharmaceutical Technology

APRIL 18, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These can serve as an important component of a vaccine.

Protein 147

Protein Vaccination Vaccine Production 147

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.

Clinical Trials 52

Clinical Trials Clinical Trials Pharma Companies Vaccination 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

pharmaphorum

MAY 11, 2021

Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body. Because the company will be targeting well-established biology, it expects to have a shorter development timelines and higher success rates than traditional biopharma.

RNA 98

RNA Drugs Protein Immune Response 98

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility. Karim Beguir – InstaDeep.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

Drug Discovery World

JULY 5, 2023

Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. MG: I am responsible for Agilent’s cancer segment. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent?

Research 98

Research Protein Scientist Immune Response 98

Find Me Cure

OCTOBER 13, 2019

If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. HER2 is a protein that plays an important role in cancer cell growth and is found on the surface of cancer cells in a very high quantity in about 10-20% of breast cancers.

Development 52

Development DNA Clinical Trials Clinical Trials 52

XTalks

NOVEMBER 30, 2023

Global entities such as the WHO, the Global Fund and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have developed comprehensive strategies aligned with Sustainable Development Goal (SDG) target 3.3, These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Cloudbyz

MARCH 6, 2024

Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins. Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology.

Gene 72

Gene Immune Response Manufacturing Gene Therapy 72

Delveinsight

DECEMBER 13, 2020

Due to hepatitis C, most people develop cirrhosis, or scarring of the liver, before liver cancer; about 5–25% of patients with chronic hepatitis C develop cirrhosis over 10–20 years. Research and development in Hepatitis. Frequent side effects and average sustained viral response (SVR) was observed with IFNa treatment.

Genotype 52

Genotype FDA Approval DNA Drugs 52

Pharmaceutical Technology

NOVEMBER 22, 2022

Vaccines are our number one weapon in the fight against infectious diseases, but their development has historically involved a long and complex process taking up to a decade. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. million in funding to support this work.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

Drug Discovery World

MAY 11, 2023

Kerstin Pohl , Senior Global Marketing Manager, Gene Therapy & Nucleic Acid at SCIEX, looks at the application of liquid chromatography-mass spectrometry for analysing host cell proteins. Host cell proteins (HCPs) – proteins derived from the host cells used for viral production—are one class of process-related impurities.

Production 52

Production Gene Protein Vaccination 52

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Genetics 52

Genetics Research Medicine Clinical Research 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

pharmaphorum

FEBRUARY 22, 2021

Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year. In December interim phase 1/2 trial results showed the vaccine produced a lower immune response in older adults.

Vaccination 89

Vaccination Vaccine Recombinant DNA Technology Trials 89

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . Thompson says that the development of Covid-19 vaccines, which used mRNA technology, resulted in wider acceptance for cell and gene therapies. . “On

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. Business Development/Other Developments. Research and development expenses increased 20 percent to $1.673 billion, or 24.8 on a non-GAAP basis.

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

OCTOBER 14, 2020

Potential Development of Human Monoclonal Antibody Therapeutics to SARS-CoV-2. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. CHATHAM, N.J., About TNX-1800. 1 Noyce RS, et al.

Vaccination 40

Vaccination Vaccine Development Medicine 40

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. This potentially re-energises the immune system to fight cancers.” Here are their answers.

Research 52

Research Drugs Protein RNA 52

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

Delveinsight

DECEMBER 3, 2020

Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. An overactivity of complement damages cells in the macula in geographic atrophy. Merck chooses TriNKET cancer immunotherapy program.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Drug Discovery World

DECEMBER 15, 2022

These platforms all induce double strand cuts in the chromosomal DNA that can be sealed by the cell, leading to a specific gene disruption, or resulting in a new target site for inserting DNA segments. Reduce/eliminate chromosomal disruptions caused by double-strand DNA breaks. In one example, Choi et al.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

The Pharma Data

APRIL 7, 2023

Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.

Trials 40

Trials DNA Medicine Development 40

The Pharma Data

JANUARY 21, 2021

Louis developed a simple and rapid blood test that can predict patients at highest risk of most severe COVID-19 complications or death. The test valuates mitochondrial DNA levels. Our study suggests that tissue damage may be one cause of this spiral, since the mitochondrial DNA that is released is itself an inflammatory molecule.”.

Research 52

Research DNA Hormones Vaccination 52

Drug Discovery World

OCTOBER 17, 2023

BN : Our bodies consist of an incredibly complex network of about 35 trillion cells divided into as many as 300 cell types that fulfil distinct roles in development, homeostasis, and disease. This limits its efficacy in later stages of drug development or in the discovery and characterisation of biomarkers.

Gene Expression 52

Gene Expression Drugs Protein Gene 52

XTalks

MARCH 10, 2021

Along with COVID-19 vaccine authorizations, the US Food and Drug Administration (FDA) remains committed to increasing access to COVID-19 tests and supporting their development, having authorized three new tests recently for emergency use. The products encompass molecular, antigen and T cell-based testing approaches.

Protein 98

Protein RNA Antibody Production 98

Drug Discovery World

FEBRUARY 2, 2023

Bryan Oronsky , Chief Development Officer at EpicentRx, discucsses how one drug sourced from the defense and aerospace industry, could have many potential disese targets. A late-stage clinical trial in head and neck cancer for the treatment of severe oral blistering or oral mucositis caused by radiation therapy is planned.

Manufacturing 52

Manufacturing Clinical Trials Clinical Trials Drugs 52

Drug Discovery World

FEBRUARY 8, 2023

This helps ensure a high concentration of loaded capsids and adequate removal of impurities, such as host cell proteins and DNA. The threat of empty capsids Capsids are the protein shell that would usually enclose the genetic material of a virus. What makes an ideal AAV analytics tool for process development?

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

Drug Discovery World

OCTOBER 6, 2022

In pursuit of this, the number of new therapeutics in development has boomed. New classes of therapies have added to this growth, including immune checkpoint inhibitors and genome targeted therapies. Both the binary and quantitative have relied on measurement of protein, DNA, and more recently, RNA.

Medicine 52

Medicine Clinical Trials Clinical Trials Genome 52

The Pharma Data

JANUARY 13, 2021

The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan. The new vaccine is made up of a deactivated cold virus into which scientists cut-and-paste a genetic version of the “spike” protein used by the coronavirus to infect cells.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

The Pharma Data

DECEMBER 27, 2020

The drug is a humanized IgG4 monoclonal antibody that blocks CCR5 and is being developed for COVID-19, HIV and metastatic triple-negative breast cancer. The drug is a topical ointment applied to the lower lid to address the build-up and shedding of proteins at the opening of the Meibomian gland. Non-COVID-19-Related. Most Read Today.

Trials 52

Trials Antibody Gene Therapy Clinical Trials 52

Drug Discovery World

OCTOBER 21, 2022

A major breakthrough in the technology was the development of biologically active fluorescent reagents that could be detected by the instruments. Fluorescent molecules that are conjugated to antibodies can be grouped according to their chemical structure into small organic dyes, protein-based dyes, and polymer or multimer dyes.

Reagent 52

Reagent Antibody Drugs Protein 52

The Pharma Data

DECEMBER 20, 2020

It is an optimized, non-chemically modified mRNA that codes for the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus. Pfizer and BioNTech announced additional data on neutralizing antibody and T-cell responses from their Phase I/II trial of their COVID-19 vaccine conducted in Germany.

Trials 52

Trials Gene Therapy Vaccination Vaccine 52

pharmaphorum

JULY 26, 2022

Fortunately, since the emergence of the first treatment in 1987 and the development of effective countermeasures, the condition is no longer a terminal one. At a basic level, the virus’s protein ‘coat’ and the enzymes it uses to gain control of the host cell’s DNA mutate frequently, making it difficult to target with therapeutics.

Gene Therapy 140

Gene Therapy Protein Vaccination Vaccine 140

The Pharma Data

JUNE 30, 2021

development lead, gastrointestinal cancers, Bristol Myers Squibb. Efficacy outcome measures included objective response rate (ORR) as assessed by blinded independent central review using Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and duration of response (DOR). Waxman, M.D.,

Trials 52

Trials Genome Genomics Containment 52

XTalks

SEPTEMBER 14, 2020

And in truth, the companies the White House picked were pretty savvy as several are current front-runners in the race to develop a vaccine. The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. Moderna’s COVID-19 Vaccine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92